“Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor”. 2025. Canadian Hematology Today 4 (3): 24–35. https://doi.org/10.58931/cht.2025.4379.